Isoray - ISR Stock Forecast, Price & News

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Isoray in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ISR shares.
View ISR analyst ratings or view top-rated stocks.

1 equities research analysts have issued 1 year price objectives for Isoray's shares. Their ISR share price forecasts range from $1.25 to $1.25. On average, they predict the company's share price to reach $1.25 in the next twelve months. This suggests a possible upside of 237.8% from the stock's current price.
View analysts price targets for ISR or view top-rated stocks among Wall Street analysts.

Isoray's stock was trading at $0.38 at the beginning of 2022. Since then, ISR stock has decreased by 2.6% and is now trading at $0.37.
View the best growth stocks for 2022 here.

Isoray saw a decrease in short interest during the month of July. As of July 31st, there was short interest totaling 621,400 shares, a decrease of 6.9% from the July 15th total of 667,700 shares. Based on an average daily trading volume, of 271,800 shares, the days-to-cover ratio is currently 2.3 days. Approximately 0.9% of the company's stock are short sold.
View Isoray's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, September 19th 2022.
View our ISR earnings forecast.

Isoray, Inc. (NYSEAMERICAN:ISR) issued its earnings results on Wednesday, November, 10th. The healthcare company reported ($0.02) EPS for the quarter, missing the consensus estimate of ($0.01) by $0.01. The healthcare company had revenue of $2.56 million for the quarter, compared to analysts' expectations of $2.58 million. Isoray had a negative trailing twelve-month return on equity of 9.19% and a negative net margin of 48.05%.

Based on aggregate information from My MarketBeat watchlists, some companies that other Isoray investors own include Brainstorm Cell Therapeutics (BCLI), OPKO Health (OPK), Bausch Health Companies (BHC), Anavex Life Sciences (AVXL), TherapeuticsMD (TXMD), Catalyst Pharmaceuticals (CPRX), MannKind (MNKD), CTI BioPharma (CTIC), Idera Pharmaceuticals (IDRA) and Palatin Technologies (PTN).

Isoray trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ISR."

Isoray's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Perkins Capital Management Inc. (2.05%) and Taylor & Morgan Wealth Management LLC (0.55%). Insiders that own company stock include Jonathan Robert Hunt, Lori A Woods, Mark John Austin, Michael Krachon, Philip J Vitale and William Cavanagh.
View institutional ownership trends.

Shares of ISR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ISR stock can currently be purchased for approximately $0.37.

Isoray (NYSEAMERICAN:ISR) has a market capitalization of $52.55 million and generates $10.05 million in revenue each year. The healthcare company earns $-3,390,000.00 in net income (profit) each year or ($0.05) on an earnings per share basis.

Isoray's mailing address is 350 Hills St Ste 106, RICHLAND, WA 99354-5511, United States. The official website for the company is isoray.com. The healthcare company can be reached via phone at (509) 375-1202, via email at dbabcock@isoray.com, or via fax at 509-267-3670.